The California Institute for Regenerative Medicine (CIRM) has awarded $14.4 million to support two new clinical trials targeting aggressive cancers.
The awards fund one trial for blood cancers and another for pediatric brain tumors. Together, they bring the total number of CIRM-funded clinical trials to 70.
Both projects aim to expand treatment options for patients with serious diseases that often have limited therapies and poor outcomes.
Targeting Blood Cancer Stem Cells
CIRM awarded $6 million to Immune-Onc Therapeutics to support a clinical trial for patients with acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML).
AML is an aggressive blood cancer that affects about 20,000 people in the United States each year. Despite available treatments, the five-year survival rate remains only about 25 percent.
CMML is another blood cancer that can progress to AML in approximately 15 to 30 percent of patients.
Dr. Paul Woodard and his team will lead the trial.
Researchers will evaluate an antibody therapy called IO-202, which targets leukemic stem cells. These cells can drive disease progression and contribute to relapse.
The therapy blocks a signaling protein known as LILRB4. Researchers have linked high levels of LILRB4 to poorer outcomes in AML patients.
The goal is to achieve complete remission and improve long-term survival.
New Hope for Children With Brain Tumors
CIRM also awarded $8.4 million to City of Hope to support a clinical trial for children with malignant brain tumors.
Brain tumors are the most common solid tumors in children. Each year, approximately 5,000 children receive a brain tumor diagnosis in the United States.
Dr. Leo D. Wang and his team will test a chimeric antigen receptor T-cell therapy, commonly known as CAR-T therapy.
CAR-T therapy uses a patient’s own immune cells to fight cancer.
Researchers collect T cells from the patient and genetically modify them to recognize cancer cells. The engineered cells are then returned to the patient, where they can identify and attack tumors.
The trial will evaluate whether this approach can improve outcomes for children with aggressive brain cancers.
Expanding the Pipeline of Regenerative Medicine Therapies
CIRM President and CEO Dr. Maria T. Millan said both projects align closely with the agency’s mission.
“Funding the most promising therapies for aggressive blood cancer and brain tumors has always aligned with CIRM’s mission,” she said.
Dr. Millan noted that these studies represent the first of many stem cell and regenerative medicine programs that CIRM plans to support through funding authorized under Proposition 14.
Moving Promising Therapies Toward Patients
Patients with aggressive blood cancers and pediatric brain tumors urgently need new treatment options.
By supporting clinical trials at this stage, CIRM helps move promising therapies from the laboratory into patient testing.
These investments reflect a broader commitment to accelerating regenerative medicine and bringing innovative treatments to people with the greatest unmet medical needs.

Nice article